The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
Clinical Trials Arena on MSN
MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial
"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. Other ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
As Novo Nordisk races to get an oral successor to the weight loss sensation Wegovy through clinical trials, Viking Therapeutics is raising its sails for an attack. The biotech unveiled data from a ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...
The possibility of a long-awaited change in the treatment of male baldness has been raised by Cosmo Pharmaceuticals’ ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel ...
A new phase shifter does not need clean-room facilities for fabrication, so is inexpensive to manufacture. The liquid-metal enabled phase shifting elements have a 'passive' nature, unlike the 'active' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback